Ticker Symbol: RGNX
Regenxbio Inc
$31.84 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001590877
Company Profile
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 9600 Blackwell Rd Ste 210
Website: www.regenxbio.com
CEO: Kenneth Mills
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $16.09
Change:
$0.18
(
1.13%)
Days Range: $15.77 - $16.39
Beta: 1.31
52wk. High: $25.54
52wk. Low: $14.90
Ytd. Change -27.93%
50 Day Moving Average: $16.88
200 Day Moving Average: $18.39
Shares Outstanding: 43960108
Valuation
Market Cap: 70.7B
PE Ratio: -2.55
EPS (TTM): -6.32
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A